December 3, 2019

IntegriChain Implements Data-Science-Driven Stewardship of Specialty Pharmacy Data for Multiple Top-30 Life Sciences Manufacturers

Data Stewardship Improves Quality and Actionability of Aggregated Specialty Pharmacy Data

EVP Josh Halpern to Present Thought Leadership on Data Stewardship at CBI Trade & Channel 

Philadelphia, PA, December 3, 2019 – IntegriChain, a leading life sciences commercial data and analytics company that helps drives patient outcomes, today announced that multiple top-30 Life Sciences manufacturers have implemented its stewardship and refining solutions to improve the quality and actionability of specialty pharmacy data. These solutions, based on recent data science advancements in the ICyte Platform, overcome the industry challenge of immature patient data sets that includes non-standardize data from hundreds of data suppliers delivered with varied quality. IntegriChain Co-Founder and EVP Josh Halpern will present more on this topic during his presentation, “The State of Patient Status Visibility and the Use of Artificial Intelligence to Drive Specialty Channel Insights,” at CBI Trade & Channel, beginning today in Philadelphia.

“While legacy specialty pharmacy data aggregators provide longitudinal de-identification and ingestion of raw patient status data, they have failed to address the costly errors and gaps in patient status and sub-status data that prevent specialty brands from taking action to improve patient access outcomes,” said Halpern. “The ICyte Platform automates stewardship, cleansing and refining processes to address the industry’s number-one challenge — poor data quality. With enriched aggregated patient status data, manufacturers can transform specialty pharmacy account management, take action on stalled patient cases, and drive patient outcomes.”

IntegriChain has defined an industry best practice operational model to implement these enriched data and analytics solutions without disrupting a manufacturer’s existing processes. In addition, IntegriChain has developed new data-quality-focused KPIs that empower life sciences manufacturers to optimize their specialty data investment.

“Specialty pharmacy data quality is critical to taking action on patient access barriers and improving outcomes,” Halpern added. “We’ve introduced a suite of daily, weekly, and quarterly data quality KPIs that empower our customers to hold pharmacies accountable, in some instances financially, for the data requirements they’ve agreed to meet.”

Benchmark Data to Be Presented at Trade & Channel
During the CBI Trade & Channel Conference presentation, Halpern will present benchmark data compiled by IntegriChain’s data science team that illustrates the depth of the quality challenge life sciences manufacturers must address to achieve better patient access visibility. The most pressing specialty pharmacy data issues include patient status update timeliness, incorrect patient access sequencing, and poor sub-status utilization. Industry benchmarks are available from IntegriChain upon request. Halpern’s presentation will be on Wednesday, December 4, at 4:15 pm ET.

About IntegriChain Patient Access Solutions
Patient Data Aggregation: Aggregation of longitudinal, de-identified patient status, sub-status, and dispense records reported by network specialty pharmacies and reimbursement hub to deliver the highest quality master data.

Refined Patient Data: Employment of industry-leading data science and enrichment algorithms to greatly improve patient access visibility and the quality and actionability of specialty pharmacy patient status data.

Specialty Pharmacy Analytics: Actionable patient access insights powered by enriched patient status data, allowing specialty manufacturers to measure provider, payer, and SP impact on KPI metric performance. 

About IntegriChain
IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our mission is to help all stakeholders in pharmaceutical market access and commercialization drive patient outcomes. Our data-science-driven ICyte Platform and solutions uniquely focus on overcoming challenges after the patient and provider commit to therapy. More than 180 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, and Pune, India. For more information, visit and our blog, or follow us on Twitter @IntegriChain and LinkedIn.

Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 |

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article